These steps translate to synergic anti-inflammatory activity at multiple sites, through a reduction in the endothelial surface exposure of cell adhesion molecules, downregulation of IL-6 and IL-23 release from monocytes, and negative regulation of the subset T-helper cells 17, the culprit in modern therapeutic approaches for atherosclerosis [64,65]. Here, IL6 is linked to atherosclerosis.